50 pág.


Disciplina:Anatomia Humana22.109 materiais908.017 seguidores
Pré-visualização32 páginas
for type 2 diabetes mellit�s�� N Engl J Med 2000��342�� �0�–�2��

2�2�� R�ggenenti, P, Fassi, A, Ilieva, AP�� Preventing microalb�min�ria in type 2 diabetes�� N Engl J
Med 2004��������4���

2�3�� Parving H�H, Lehnert H, Brochner�Mortensen J, Gomis R, Andersen S, Arner P�� The effect
of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes��
N Engl J Med 200���34���870–8 �A���

2�4�� Atkins RC, Briganti EM, Lewis JB, H�nsicker LG, Braden G, Champion de Crespigny PJ,
DeFerrari G, Dr�ry P, Locatelli F, Wiegmann TB, Lewis EJ�� Protein�ria red�ction and progres�
sion to renal fail�re in patients with type 2 diabetes mellit�s and overt nephropathy�� Am J
Kidney Dis�� 200���4���28��7��

2���� de Zee�w D, Rem�zzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper
ME, Mitch WE, Brenner BM�� Protein�ria, a target for renoprotection in patients with type
2 diabetic nephropathy�� lessons from RENAAL��Kidney Int 2004�������230��20��

2����� Baigent C, Keech A, Kearney PM, Blackwell L, B�ck G, Pollicino C, Kirby A, So�rjina T, Peto
R, Collins R, Simes R�� Cholesterol Treatment Trialists’ �CTT� Collaborators�� Efficacy and
safety of cholesterol�lowering treatment�� prospective meta�analysis of data from �0,0���
participants in �4 randomised trials of statins�� Lancet 200���3�������2��7�78��

2�7�� III Diretrizes Brasileiras sobre dislipidemias e diretriz de prevenção da aterosclerose do
departamento de aterosclerose da sociedade brasileira de cardiologia�� Arq Bras Cardiol
200���77�s�pl III�����48��

2�8�� Gr�ndy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, H�nninghake DB, Pasternak RC, Smith
SC Jr, Stone NJ�� NCEP Report�� Implications of Recent Clinical Trials for the National Cholesterol
Ed�cation Program Ad�lt Treatment Panel III G�idelines�� Circ�lation 2004����0��227–23���

2���� Goldstein LB, Adams R, Becker K, F�rberg CD, Gorelick PB, Hademenos G, Hill M, Howard
G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo
GJ�� Primary prevention of ischemic stroke�� A statement from the Stroke Co�ncil of the
American Heart Association�� Circ�lation 200����03�����3��82��

220�� Schrader J, L�ders S, K�lschewski A, Hammersen F, Plate K, Berger J, Zidek W, Domi�
niak P, Diener HC�� MOSES St�dy Gro�p�� Morbidity and Mortality After Stroke, Eprosartan
Compared with Nitrendipine for Secondary Prevention�� principal res�lts of a prospective
randomized controlled st�dy �MOSES��� Stroke 200� 3���������2�8�2����

22��� Britton M, Carlsson A, de Faire U�� Blood press�re co�rse in patients with ac�te stroke and
matched controls�� Stroke ��8�����7��8����8��4��

222�� Oliveira�Filho J, Silva SC, Trab�co CC, Pedreira BB, So�sa EU, Bacellar A�� Detrimental effect of blood
press�re red�ction in the first 24 ho�rs of ac�te stroke onset�� Ne�rology 2003��������047��0����

223�� Leonardi�Bee J, Bath PM, Phillips SJ, Sandercock PA�� Blood press�re and clinical o�tcomes
in the International Stroke Trial�� Stroke 2002��33���3����320��

224�� Toni D, Chamorro A, Kaste M, Lees K, Wahlgren NG, Hacke W�� Ac�te treatment of ischaemic
stroke�� Cerebrovasc Dis 2004���7�s�ppl 2���30�4����

22��� Mattle HP, Kappeler L, Arnold M, Fischer U, Nedeltchev K, Remonda L, Jakob SM, Schroth
G�� Blood press�re and vessel recanalization in the first ho�rs after ischemic stroke�� Stroke

22���� Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tam�ra A�� Blood press�re manage�
ment in ac�te intracerebral hemorrhage�� relationship between elevated blood press�re and
hematoma enlargement�� Stroke 2004��3����3��4��3��7��

227�� Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D,
Mayberg M, Tilley B, Zabramski JM, Z�ccarello M�� G�idelines for the management of spon�
taneo�s intracerebral hemorrhage�� a statement for healthcare professionals from a special
writing gro�p of the Stroke Co�ncil, American Heart Association�� Stroke ������30���0�������

228�� Baigent C, Collins R, Appleby P, Parish S, Sleight P,Peto R�� ISIS�2�� �0 year s�rvival among
patients with s�spected ac�te myocardial infarction in randomisedcomparison of intraveno�s
streptokinase, oral aspirin, both, or neither�� The ISIS�2 �Second International St�dyof Infarct
S�rvival� CollaborativeGro�p�� BMJ, ���8��3����7�4�����337–43��

22��� Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE�� Long�term effects of diltia�
zem and verapamil on mortality and cardiac events in non�Q�wave ac�te myocardial infarc�
tion witho�t p�lmonary congestion�� post hoc s�bset analysis of the m�lticenter diltiazem
postinfarction trial and the second danish verapamil infarction trial st�dies�� Am J Cardiol

230�� DATASUS�� Morbidade Hospitalar do Sistema Único de Saúde�� http��//tabnet��datas�s��gov��
br/tabcgi��exe?sih/cnv/mi�f��def�� Acessado em �8 de novembro de 200���

23��� The CONSENSUS Trial St�dy Gro�p�� Effects of enalapril on mortality in severe congestive
heart fail�re�� Res�lts of the Cooperative North Scandinavian Enalapril S�rvival St�dy �CON�
SENSUS��� N Engl J Med ��87��3����23����42��3���

232�� Pfeffer MA�� McM�rray JJ�� Velazq�ez EJ�� Ro�lea� JL�� Kober L�� Maggioni AP�� Solomon SD��
Swedberg K�� Van de Werf F�� White H�� Leimberger JD�� Henis M�� Edwards S�� Zelenkofske S��
Sellers MA�� Califf RM�� Valsartan, captopril, or both in myocardial infarction complicated by
heart fail�re, left ventric�lar dysf�nction, or both�� N Engl J Med 2003��34��20����8�3��0����

233�� McM�rray JJ�� Ostergren J�� Swedberg K�� Granger CB�� Held P�� Michelson EL�� Olofsson B��
Y�s�f S�� Pfeffer MA�� Effects of candesartan in patients with chronic heart fail�re and re�
d�ced left�ventric�lar systolic f�nction taking angiotensin�converting�enzyme inhibitors�� the
CHARM�Added trial�� Lancet 2003��3��2��38�����7��7�7���

234�� Hjalmarson A, Goldstein S, Fagerberg B, Wedel H Waagstein F, Kjeksh�s J, Wikstrand J��
MERIT�HF St�dy Gro�p�� Effects of controlled�release metoprolol on total mortality, hospi�
talizations, and well�being in patients with heart fail�re�� The Metoprolol CR/XL Randomized
Intervention Trial in Congestive Heart Fail�re �MERIT�HF��� JAMA, 2000��283���2��–302��

23��� Leizorovicz A�� Lechat P�� C�cherat M�� B�gnard F�� Bisoprolol for the treatment of chronic heart
fail�re�� a meta�analysis on individ�al data of two placebo�controlled st�dies��CIBIS and CIBIS
II�� Cardiac Ins�fficiency Bisoprolol St�dy�� Am Heart J 2002���43�2���30��7��

23���� A trial of the beta�blocker b�cindolol in patients with advanced chronic heart fail�re�� N Engl J
Med 200���344�22�����������7��

237�� Packer M�� O’Connor CM�� Ghali JK�� Pressler ML�� Carson PE�� Belkin RN�� Miller AB�� Ne�berg
GW�� Frid D�� Wertheimer JH�� Cropp AB�� DeMets DL�� Effect of amlodipine on morbidity and
mortality in severe chronic heart fail�re�� Prospective Randomized Amlodipine S�rvival Eval��
ation St�dy Gro�p�� N Engl J Med ������� 33���������07��4��

238�� Cohn JN, Ziesche S, Smith R, Anad I, D�nkman WB, Loeb H, Cintron G, Boden W, Bar�ch
L, Rochin P, Loss L�� Vasodilator�Heart Fail�re Trial �V�HeFT� St�dy Gro�p�� Effect of calci�m
antagonist felodipine as s�pplementary vasodilator therapy in patients with chronic heart
fail�re treated with enalapril�� V�HeFT III�� Circ�lation ���7�������8���–��3��

23��� Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J�� Randomi�
zed Aldactone Eval�ation St�dy Investigators�� The effect of spironolactone on morbidity and
mortality with severe heart fail�re�� N Engl J Med ������34���70�–�7��

240�� Pitt B�� Remme W�� Zannad F�� Neaton J�� Martinez F�� Roniker B�� Bittman R�� H�rley S�� Kleiman
J�� Gatlin M�� Eplerenone, a selective aldosterone blocker, in patients with left ventric�lar dys�
f�nction after myocardial infarction�� N Engl J